Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(39 sites)
United States
Emory Winship Cancer Institute, Atlanta, Georgia Community Health Network, Indianapolis, Indiana The Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland Nebraska Cancer Specialists, Omaha, Nebraska University of Nebraska Medical Center, Omaha, Nebraska Penn Medicine - Abramson Cancer Center Perelman, Philadelphia, Pennsylvania France
Institute Bergonie, Bordeaux Gustave Roussy, Villejuif Spain
Hospital Germans Trias i Pujol/ ICO Badalona, Badalona University Hospital Vall D'Hebron, Barcelona Hospital Clínic de Barcelona, Barcelona ICO L'Hospitalet (Instituto Catalán de Oncología), Barcelona Hospital Universitario de La Princesa, Madrid Hospital Universitario Gregorio Marañón, Madrid Hospital Infanta Leonor, Madrid Hospital Universitario Ramón y Cajal, Madrid Hospital Universitario 12 de Octubre, Madrid CIOCC Hospital Universitario HM Sanchinarro, Madrid Universidad de Navarra, Pamplona Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana, Valencia Sweden
Karolinska Comprehensive Cancer Center, Stockholm United Kingdom
The Royal Marsden, Sutton, Surrey The Clatterbridge Cancer Centre NHS Foundation Trust,, Bebington University Hospitals Bristol, Bristol University Hospital of Wales, Cardiff Royal Derby Hospital, Derby Western General Hospital, Edinburgh Gartnavel General Hospital, Glasgow Leicester Royal Infirmary, Leicester St Bartholomew's Hospital, London Sarah Cannon Research Institute UK, London NIHR University College London Clinical Research Facility, London The Christie Hospital, Manchester Newcastle upon Tyne Hospitals, Newcastle upon Tyne